Press Releases Cellectis S.A.

Equities

ALCLS

FR0010425595

Market Closed - Euronext Paris Other stock markets 11:35:22 2024-06-07 am EDT			5-day change	1st Jan Change
2.36 ^EUR	0.00%		-2.07%	-14.62%

Jun. 07	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	MT
Jun. 06	Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cellectis S A : Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia	Jun. 04	PU
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia	Jun. 04	GL
Cellectis S A : Environmental Social & Governance Report - March 2024	Jun. 04	PU
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024	May. 29	GL
Cellectis S A : Corporate Presentation - May 2024	May. 28	PU
Cellectis Reports Financial Results for First Quarter 2024	May. 28	GL
Cellectis Reports Financial Results for First Quarter 2024	May. 28	AQ
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024	May. 27	GL
Cellectis S A : NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHOLDERS - Form 6-K	May. 24	PU
Cellectis S A : Report of the board of directors to the Combined Shareholders’ Meeting - June 28, 2024	May. 24	PU
Cellectis S A : Notice of Meeting Combined General Meeting of Shareholders June 28, 2024	May. 24	PU
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	May. 16	PU
Cellectis S A : Corporate Presentation - May 2024	May. 13	PU
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	May. 06	PU
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca	May. 06	GL
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer	May. 02	GL
Cellectis S A : Announces Completion of the Additional Equity Investment by AstraZeneca	May. 01	PU
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023	Apr. 29	GL
Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 23	AQ
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 22	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cellectis S.A.

Equities

ALCLS

FR0010425595

Press Releases

Filters